Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $7.40.

ATNM has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, Stephens reaffirmed an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ATNM. Vontobel Holding Ltd. purchased a new position in shares of Actinium Pharmaceuticals in the 4th quarter valued at about $32,000. Interchange Capital Partners LLC acquired a new stake in Actinium Pharmaceuticals in the third quarter valued at approximately $37,000. Barclays PLC lifted its stake in Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals during the 2nd quarter worth approximately $92,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter valued at approximately $112,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Stock Performance

NYSE:ATNM opened at $1.16 on Friday. Actinium Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $10.24. The company has a 50 day moving average price of $1.29 and a 200 day moving average price of $2.14. The stock has a market capitalization of $36.19 million, a P/E ratio of -0.83 and a beta of 0.12.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).